<DOC>
	<DOCNO>NCT01071044</DOCNO>
	<brief_summary>Over past decade , Rochester Center Behavioral Medicine ( RCBM ) evaluate many patient attention deficit hyperactivity disorder ( ADHD ) . A recurrent finding patient history unexplained fatigue musculoskeletal pain . Treatment patient clinic reveal underlying ADHD treat psychostimulant medication , many patient report significant improvement regard fatigue musculoskeletal pain . Patients report less subjective fatigue pain note overall functional improvement , although initial primary objective treatment attention hyperactivity problem . We speculate stimulant efficacious offer two distinct clinical property . 1 ) anti-fatigue property 2 ) property allow patient filter extraneous stimulus ( i.e . chronic muscle pain ) .</brief_summary>
	<brief_title>Efficacy Safety Lisdexamfetamine Dimesylate Adults With Chronic Fatigue Syndrome</brief_title>
	<detailed_description>As result finding RCBM develop chronic fatigue/fibromyalgia clinic early 2000 's . This clinic staffed board-certified rheumatologist psychiatric staff RCBM . Through major referral hospital area , patient self-identified fibromyalgia chronic fatigue refer clinic . Over eighteen month , evaluate 75 patient , find patient comprehensive evaluation , nearly 70 percent also history ADHD , inattentive combine type . Diagnosis make use clinical history standardize symptom checklist . Oftentimes , ADHD previously undiagnosed . This finding support link ADHD FMS/CFS . Results evaluation reinforce initial finding : patient treat ADHD symptom also show reduction chronic pain fatigue symptom . This true regardless previous ( unsuccessful ) therapies treat fibromyalgia . As result finding , conduct control study demonstrate efficacy lisdexamfetamine dimesylate ( LDX ) control fatigue symptom patient present chronic fatigue syndrome . This double-blind , placebo-controlled study period 8 week , subject randomize either LDX placebo . We evaluate subject standardize pain , fatigue ADHD assessment scale .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Fatigue Syndrome , Chronic</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>BRIEFA Global Executive Composite score ( GEC ) ≥ 65 , Behavioral Regulation Index score ( BRI ) ≥ 65 , Metacognition Index score ( MI ) ≥ 65 . Subjects must meet consensus criterion chronic fatigue syndrome . Provide write informed consent participation trial complete studyrelated procedure . 1860 year time consent Male nonpregnant female breastfeed . Females reproductive potential must agree use medically accept mean contraception engage sexual intercourse time study . Are able swallow study medication . CFS executive function impairment present diagnosable Serious comorbid psychiatric condition Subjects pregnant , nursing , intend become pregnant Subjects psychostimulant regimen last six month Subjects medical condition would affect psychostimulant medication Subjects low intelligence , unable communicate effectively study team</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Chronic Fatigue Syndrome</keyword>
</DOC>